News

Mer­ck and Kelun-Biotech re­vealed Phase 3 breast can­cer da­ta for the lead an­ti­body-drug con­ju­gate in their po­ten­tial­ly $12 bil­lion part­ner­ship. In a Phase 3 tri­al … ...
Senate Finance Committee Chair Ron Wyden (D-OR) is urging HHS to take a stronger stance on healthcare companies' cybersecurity practices as the healthcare system is still piecing together what ...
Bristol Myers Squibb said its KRAS cancer drug Krazati met the primary endpoint in a Phase 3 confirmatory trial in patients with non-small cell lung cancer, according to new data ...
Madri­gal Phar­ma­ceu­ti­cals is “mak­ing great progress” on the roll­out of its NASH drug Rezd­if­fra, ex­ec­u­tives said less than a month post-launch. Rezd­if­fra was ...
Pacific Biosciences, or PacBio for short, made its name in long-read DNA sequencing — the technology recently used to sequence the entire human genome — filling in a ...
In the days fol­low­ing the US Supreme Court’s roll­back of fed­er­al abor­tion rights, more than 100 women biotech ex­ec­u­tives came to­geth­er in an ...
Up un­til re­cent­ly, Al­ban de La Sablière was Sanofi ’s chief deal­mak­er, re­port­ing di­rect­ly to CEO Paul Hud­son with­out of­fi­cial­ly be­ing a C-suite ex­ec­u­tive ...
The next generation of Operation Warp Speed is coming soon, and this time it's going to take aim at rare diseases, Peter Marks, the director of the FDA's Center for ...
Tech, com­merce-fo­cused in­vestor un­veils $500M bet on health­care ...
CVS Health is shut­ting down the clin­i­cal tri­als busi­ness that it launched just two years ago, part of an ef­fort to fo­cus on its core … ...
The FDA is hoping its latest solution will stave off the continued shortage of cisplatin, a key drug used in treating several types of cancer. Beginning ...